Reyataz (atazanavir)

HIV thrives by taking over the immune system's vital CD4 cells (white blood cells) and using their inner workings to make additional copies of itself. Reyataz belongs to a class of HIV drugs called protease inhibitors, which work by interfering with an important step in the virus's reproductive cycle.

Reyataz is approved for used only in combination with other anti-HIV medications.